Oleyl-Cortagen versus Cortagen: central and systemic rat assays
I. M. Voeyikov · 2015 · Kirov Military Medical Academy dissertation author abstract
Related evidence maps: Military & occupational ↗
Reported findings and study design
In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.
496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison
Dose, route and schedule
Central experiments: 1, 10 or 100 µg into a lateral ventricle, 5–10 minutes before testing. Systemic methods list Cortagen and Oleyl-Cortagen at 0.1 mg/kg intraperitoneally, Cortexin and Cerebrolysin at 1 mg/kg; saline control.
Protocol source ↗ · Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Oleyl-Cortagen · central self-stimulation | 159.7±16.2 → 199.1±19.1 presses/5 min (+25%) | 1 µg into the ventricle; 10 and 100 µg produced +19% and +6% without significance marks. · p<0.05 before vs after at 1 µg |
| Cortagen · central self-stimulation | 208.0±26.7 → 270.4±26.4 presses/5 min (+30%) | 100 µg into the ventricle; lower doses lacked a significance mark. · p<0.05 before vs after |
| Cortexin · central self-stimulation | 209.3±22.9 → 295.1±26.2 presses/5 min (+41%) | 100 µg into the ventricle; 1 and 10 µg lacked significance marks. · p<0.05 before vs after |
| Cerebrolysin · central self-stimulation | 220.8±21.2 → 280.2±14.2 presses/5 min (+27%) | 10 µg into the ventricle; 1 and 100 µg lacked significance marks. · p<0.05 before vs after |
| Anxiety-related behavior | Oleyl-Cortagen’s central maze response was described as weaker than Cortagen’s | The direction and magnitude depend on assay and dose; lipidation did not improve every endpoint. |
Author abstract Table 4 · lateral-hypothalamic self-stimulation
| Preparation, central dose | Before (presses/5 min) | After (presses/5 min) | After (% of before) | Mismatch coefficient before → after |
|---|---|---|---|---|
| Saline | 175.5±18.1 | 170.7±17.4 | 98±10 | 0.59±0.05 → 0.57±0.05 |
| Cortexin 1 µg | 161.0±15.9 | 150.2±25.1 | 93±17 | 0.54±0.06 → 0.64±0.04 |
| Cortexin 10 µg | 193.2±18.8 | 204.0±22.2 | 106±11 | 0.55±0.05 → 0.55±0.06 |
| Cortexin 100 µg | 209.3±22.9 | 295.1±26.2* | 141±9 | 0.54±0.04 → 0.45±0.05 |
| Cerebrolysin 1 µg | 184.0±26.7 | 208.8±21.5 | 114±9 | 0.58±0.06 → 0.45±0.05 |
| Cerebrolysin 10 µg | 220.8±21.2 | 280.2±14.2* | 127±5 | 0.56±0.03 → 0.35±0.02 |
| Cerebrolysin 100 µg | 239.2±15.6 | 270.5±19.3 | 113±7 | 0.55±0.04 → 0.46±0.05 |
| Cortagen 1 µg | 159.0±18.1 | 171.2±20.4 | 108±10 | 0.48±0.03 → 0.49±0.02 |
| Cortagen 10 µg | 189.6±28.1 | 226.1±29.6 | 119±11 | 0.47±0.05 → 0.47±0.04 |
| Cortagen 100 µg | 208.0±26.7 | 270.4±26.4* | 130±9 | 0.47±0.03 → 0.38±0.04 |
| Oleyl-Cortagen 1 µg | 159.7±16.2 | 199.1±19.1* | 125±7 | 0.61±0.07 → 0.50±0.04 |
| Oleyl-Cortagen 10 µg | 191.6±25.0 | 228.0±16.1 | 119±11 | 0.60±0.05 → 0.39±0.06 |
| Oleyl-Cortagen 100 µg | 207.6±13.0 | 220.0±17.7 | 106±4 | 0.58±0.04 → 0.38±0.03 |
Asterisk: p<0.05 versus the same condition before dosing. Percentages and mismatch coefficients are as transcribed; original scan and exact arm denominators were not recovered.
Behavioral effects differed by route, dose and test. The low central dose had an effect in this assay; it does not establish systemic exposure, human dosing or superiority in other outcomes.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Table 4 marks within-condition changes from before administration; no verified between-preparation superiority test.
- Central and systemic behavioral similarities do not directly measure brain penetration or tissue pharmacokinetics.
- The assays concern behavior and electrical reinforcement, not athlete endurance.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable
Review depth: Reported methods, results and evidence limitations
Source access and review scope
Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Dissertation
Citation and original source
Original source: I. M. Voeyikov. Oleyl-Cortagen versus Cortagen: central and systemic rat assays Kirov Military Medical Academy dissertation author abstract 2015.
Molekul research summary: https://molekul.io/research/voeyikov-lipid-cortagen-2015. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Oleyl-Cortagen
A lipid-modified Ala–Glu–Asp–Pro tetrapeptide evaluated in rat behavioral studies. Cortagen is the unmodified peptide and Cortexin is a separate tissue mixture.
Cortagen
Listed in the 2013 short-peptide review under the authors’ proposed brain target. This historical label is not an established indication. Underlying studies need individual review.
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.
Cerebrolysin
Porcine brain-derived peptide mixture studied in neurological disease, rehabilitation and laboratory models. Clinical results, composition analyses and unresolved archival leads are separated in this collection.